We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
From brussels sprouts to dodgy diet products, these tips from the MHRA will help you stay safe during the festive season and beyond
The MHRA has reminded healthcare professionals prescribing aripiprazole to be alert to the known risk of patients developing addictive gambling, following a rise in the number of reports received in 2023
Applications are now open for academic institutions wishing to bid for funding to collaborate with others to establish new Regulatory Science and Innovation Networks (RSINs) in innovative sectors.
…and Healthcare products Regulatory Agency (MHRA).
Patients can be reassured that Fluenz nasal spray vaccines remain safe and effective when used within the revised expiry dates.
The Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit (CEU) seized hundreds of thousands of doses of suspected illegally traded medicines, including powerful prescription-only medicines, following coordinated raids at two residential and two business…
Other effective medicines are available for epilepsy and bipolar disorder and valproate should only be used if these don’t work or aren’t suitable for an individual patient
MHRA tells patients and healthcare professionals to stop using affected gels and retailers told to withdraw affected products.
IRP is expected to further help bringing life-saving new medicines to UK patients from 1 January 2024
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
For the first time, 2- to 5-year-old patients with a certain type of cystic fibrosis could access cystic fibrosis drugs Kaftrio and Kalydeco.
As a founding member and former chair of the International Coalition of Medicines Regulatory Authorities (ICMRA), the Medicines and Healthcare products Regulatory Agency (MHRA) is joining global partners in celebrating ten years of strategic leadership and cooperation
For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support we…
Third Pharmaceuticals in the Environment (PiE) Group meeting continue discussions regarding imidacloprid and fipronil.
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
Whether you’re a patient, healthcare professional or carer, this year’s #MedSafetyWeek campaign is calling on you to help improve the safety of medical products by reporting any suspected side effects and adverse incidents t…
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
Over two million doses of illegally traded medicines valued at almost £5m seized so far this year.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).